Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CAR-T Therapies Should Impress EU Reimbursement Bodies

Executive Summary

Health authorities in Europe have different approaches to evaluating the cost-effectiveness of new drugs, but in the case of the CAR-T therapies, they are likely to look favorably on factors such as their innovative nature, the small patient populations, and the dearth of effective treatments.


Related Content

Anticancers, Orphans & The First CAR-Ts: New EU Drug Approvals In 2018
EU New Drug Approvals 2018: Anticancers, Orphans, The First CAR-Ts – And More
NICE Explains Its UK Funding Recommendation For Kymriah
CAR-T Funding: It's (Nearly) All About The Price In The UK
Interview: Measured Launch, Long Future For Gilead CAR-T In Europe


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts